Collaborations, FDA Clearances, and Technical Updates - Analyst Notes on Isis Pharmaceuticals, DexCom, Theravance Biopharma, Intrexon and Alere

NEW YORK, June 19, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), DexCom, Inc. (NASDAQ: DXCM), Theravance Biopharma, Inc. (NASDAQ: TBPH), Intrexon Corporation (NYSE: XON) and Alere Inc. (NYSE: ALR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3875-100free.

--
Isis Pharmaceuticals, Inc. Analyst Notes
On June 10, 2014, Isis Pharmaceuticals, Inc. (Isis Pharmaceuticals) announced AstraZeneca's initiation of a Phase 1 clinical study of ISIS-ARRx in patients with cancer. According to the Company, it has earned a $15 million milestone payment on the clinical advancement of ISIS-ARRx. Isis Pharmaceuticals added that AstraZeneca plans on developing ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy. Isis Pharmaceuticals Chief Operating Officer B. Lynne Parshall stated, "Together with AstraZeneca, we have expanded our efforts in developing drugs to treat patients with prostate cancer. We look forward to working closely with AstraZeneca to complete this study and to evaluate the broader therapeutic potential of ISIS-ARRx." The Company stated that it is collaborating with AstraZeneca to discover and develop antisense drugs to treat cancer. The full analyst notes on Isis Pharmaceuticals are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/ISIS/report.pdf

--
DexCom, Inc. Analyst Notes
On June 13, 2014, DexCom, Inc. (DexCom), along with Insulet Corporation, announced their intention to enable the Company's mobile App platform (currently under development) to integrate data from Insulet's OmniPod System. Additionally, the Company stated that the mobile App will be capable of incorporating glucose and other diabetes-related data from patients' devices and displaying the integrated data via a smartphone App. DexCom CEO, Terry Gregg, stated, "More than ever, we believe that effective diabetes management depends on timely and accurate data. That is why we are excited to complete development of the App and integrate data from Insulet's OmniPod system." The full analyst notes on DexCom are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/DXCM/report.pdf

--
Theravance Biopharma, Inc. Analyst Notes
On June 16, 2014, Theravance Biopharma, Inc.'s (Theravance Biopharma) stock reflected an increase of 15.85%, ending the day at $32.90. For the previous five-day trading session, Company's stock increased by 24.24% compared to the Nasdaq Composite which slipped by 0.35% during the same trading session. The full analyst notes on Theravance Biopharma are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/TBPH/report.pdf

--
Intrexon Corporation Analyst Notes
On June 16, 2014, Intrexon Corporation's (Intrexon) stock increased by 4.35%, closing the day at $25.69. Over the past six-month trading period, Company stock went up by 29.03% compared to the Dow Jones Industrial Average which reflected an increase of 5.63% during the same trading period. The full analyst notes on Intrexon are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/XON/report.pdf

--
Alere Inc. Analyst Notes
On June 16, 2014, Alere Inc. (Alere) announced that the Company has received a clearance from U.S. Food and Drug Administration (FDA) for its Alere™ i Influenza A & B test, the first and only molecular test that detects and differentiates influenza A and B virus in less than 15 minutes. Commenting on the test, Alere's Global President of Infectious Disease, Avi Pelossof, said, "By providing the speed of a rapid test with molecular technology, Alere i delivers clinically meaningful and actionable results to clinicians - enabling them to treat patients more quickly and appropriately." The full analyst notes on Alere are available to download free of charge at:

http://www.analystsreview.com/Jun-19-2014/ALR/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com .

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com .

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED